Share this article on:

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

Coll, Blaia,b; Aragonés, Gerarda; Parra, Sandrab; Alonso-Villaverde, Carlosb; Masana, Lluisb

doi: 10.1097/01.aids.0000238418.43937.3b
Research Letters

We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.

aCentre de Recerca Biomédica, Reus, Spain

bServei de Medicina Interna, Hospital Universitari Sant Joan, Reus, Spain.

Received 25 April, 2006

Accepted 10 May, 2006

© 2006 Lippincott Williams & Wilkins, Inc.